Inspire Terminates Deal With FAES Farma For Oral Bilastine
This article was originally published in The Pink Sheet Daily
Executive Summary
Company ends collaboration following a meeting with FDA last year in which the agency recommended additional clinical trial work.
You may also be interested in...
Inspiring Results For Phase III Disease-Modifying Cystic Fibrosis Drug
Inspire Pharmaceuticals' denufosol showed improvement in FEV1 versus placebo over 24 weeks.
Inspiring Results For Phase III Disease-Modifying Cystic Fibrosis Drug
Inspire Pharmaceuticals' denufosol showed improvement in FEV1 versus placebo over 24 weeks.
Inspire Drops Epinastine After Phase III Fizzle
Non-steroidal nasal spray for allergic rhinitis is the firm’s second casualty this year.